Lidbree

Lidocaine, the active ingredient in Lidbree, is an amide‑type local anesthetic presented as a sterile solution for intrauterine use. Approved in the European Union, it provides targeted numbing of uterine tissue to facilitate gynecologic procedures and reduce procedural discomfort.

GNH USA supplies Lidbree as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and offers reliable global logistics for regulated medicines. Customers benefit from consistent batch release and regulatory support.

Lidbree, a lidocaine formulation, is used for intrauterine anesthesia in several gynecologic procedures. - Hysteroscopic procedures: provides local uterine anesthesia to improve patient comfort during diagnostic and operative hysteroscopy. - IUD insertion: reduces pain associated with intrauterine device placement. - Uterine curettage or dilation and curettage: facilitates analgesia during tissue removal.

Lidocaine administered intrauterinely may be associated with the following adverse reactions.

Common Side Effects: - Uterine cramping - Vaginal bleeding or spotting - Nausea or vomiting - Dizziness or headache

Serious or Rare Side Effects: - Allergic reaction (rash, itching, anaphylaxis) - Cardiovascular toxicity (arrhythmias, hypotension) - Central nervous system toxicity (seizures, altered consciousness) - Methemoglobinemia (blue‑tinged skin, cyanosis)

When using Lidbree, consider the following precautions to ensure safe administration. - Allergy assessment: verify no known hypersensitivity to lidocaine or amide‑type anesthetics. - Cardiac monitoring: observe patients with pre‑existing conduction disorders or arrhythmias. - Dose limitation: employ the lowest effective volume to achieve anesthesia. - Hepatic function: use caution in severe liver impairment due to reduced metabolism. - Pregnancy and lactation: limit use to situations where benefits outweigh potential risks. - Store at room temperature: keep in original container, protect from moisture and light.

Lidbree may interact with other medicines; awareness of key interactions helps prevent toxicity.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): increase systemic lidocaine toxicity. - Beta‑blockers (e.g., propranolol): may enhance lidocaine’s cardiac depressant effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): raise plasma lidocaine concentrations.

Moderate Interactions (Monitor Closely): - CYP1A2 inducers (e.g., rifampicin, carbamazepine): may reduce lidocaine levels. - Concurrent use of other local anesthetics: additive neuro‑ and cardiotoxicity risk. - General anesthetics (e.g., propofol, volatile agents): may potentiate CNS depression.